Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases

[1]  A. Ascherio,et al.  Vitamin D and multiple sclerosis , 2010, The Lancet Neurology.

[2]  J. Correale,et al.  Immunomodulatory effects of Vitamin D in multiple sclerosis. , 2009, Brain : a journal of neurology.

[3]  Jie Yuan,et al.  Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy , 2009, Brain Research.

[4]  J. Knight,et al.  Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D , 2009, PLoS genetics.

[5]  B. Roos,et al.  Some new food for thought: The role of vitamin D in the mental health of older adults , 2009, Current psychiatry reports.

[6]  L. Laffel,et al.  Significant vitamin D deficiency in youth with type 1 diabetes mellitus. , 2009, The Journal of pediatrics.

[7]  C. Mathieu,et al.  Vitamin D signaling in immune-mediated disorders: Evolving insights and therapeutic opportunities. , 2008, Molecular aspects of medicine.

[8]  B. Dawson-Hughes,et al.  Vitamin D and neurocognitive dysfunction: preventing "D"ecline? , 2008, Molecular aspects of medicine.

[9]  R. Khanal,et al.  Membrane receptor‐initiated signaling in 1,25(OH)2D3‐stimulated calcium uptake in intestinal epithelial cells , 2008, Journal of cellular biochemistry.

[10]  M. Delong,et al.  Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. , 2008, Archives of neurology.

[11]  B. Nakken,et al.  The Complex Role of Vitamin D in Autoimmune Diseases , 2008, Scandinavian journal of immunology.

[12]  J. Mora,et al.  Vitamin effects on the immune system: vitamins A and D take centre stage , 2008, Nature Reviews Immunology.

[13]  M. Brentani,et al.  Expression of vitamin D receptor mRNA in the hippocampal formation of rats submitted to a model of temporal lobe epilepsy induced by pilocarpine , 2008, Brain Research Bulletin.

[14]  A. Beekman,et al.  Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. , 2008, Archives of general psychiatry.

[15]  B. Ames,et al.  Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  Jing Zhang,et al.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.

[17]  M. Laville,et al.  La carence en vitamine D chez la femme de 18 à 49 ans portant des vêtements couvrants, une réalité méconnue en médecine générale , 2008 .

[18]  C. Mathieu,et al.  Vitamin D and human health: lessons from vitamin D receptor null mice. , 2008, Endocrine reviews.

[19]  M. Laville,et al.  [Hypovitaminosis D among 18-to-49-years-old women wearing concealing clothes, an ignored reality in general practice]. , 2008, Presse medicale.

[20]  C. Gordon,et al.  Vitamin D deficiency in children and adolescents: Epidemiology, impact and treatment , 2008, Reviews in Endocrine and Metabolic Disorders.

[21]  R. Vieth,et al.  Safety of vitamin D3 in adults with multiple sclerosis. , 2007, The American journal of clinical nutrition.

[22]  Stephen B. Thomas,et al.  SOLAR ultraviolet radiation and vitamin D: a historical perspective. , 2007, American journal of public health.

[23]  K. Spach,et al.  1,25‐dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking , 2007, Journal of neuroscience research.

[24]  S. Kato,et al.  Mechanisms of transcriptional repression by 1,25(OH)2 vitamin D , 2007, Current opinion in nephrology and hypertension.

[25]  Gavin Giovannoni,et al.  Multiple sclerosis: the environment and causation , 2007, Current opinion in neurology.

[26]  A. Mackay-Sim,et al.  Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  A. Mackay-Sim,et al.  Developmental vitamin D deficiency alters brain protein expression in the adult rat: Implications for neuropsychiatric disorders , 2007, Proteomics.

[28]  R. Modlin,et al.  Therapeutic implications of the TLR and VDR partnership. , 2007, Trends in molecular medicine.

[29]  Y. Helfrich,et al.  Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. , 2007, The Journal of clinical investigation.

[30]  R. Strange,et al.  Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation , 2007, Multiple sclerosis.

[31]  A. Kalueff,et al.  Neurosteroid hormone vitamin D and its utility in clinical nutrition , 2007, Current opinion in clinical nutrition and metabolic care.

[32]  S. Vukusic,et al.  Regional variations in the prevalence of multiple sclerosis in French farmers , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  R. Khanal,et al.  Membrane receptors for vitamin D metabolites. , 2007, Critical reviews in eukaryotic gene expression.

[34]  J. Goverman,et al.  Osteopontin-induced survival of T cells , 2007, Nature Immunology.

[35]  T. Wilsgaard,et al.  Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle , 2007, Journal of Neurology.

[36]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[37]  K. Spach,et al.  IL-10 Signaling Is Essential for 1,25-Dihydroxyvitamin D3-Mediated Inhibition of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[38]  S. Madronich,et al.  Epidemic influenza and vitamin D , 2006, Epidemiology and Infection.

[39]  M. Cantorna,et al.  Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. , 2006, Progress in biophysics and molecular biology.

[40]  W. Cass,et al.  Calcitriol Protects against the Dopamine‐ and Serotonin‐Depleting Effects of Neurotoxic Doses of Methamphetamine , 2006, Annals of the New York Academy of Sciences.

[41]  S. Saha,et al.  The incidence and prevalence of schizophrenia varies with latitude , 2006, Acta psychiatrica Scandinavica.

[42]  J. Rajasingh,et al.  1,25 dihydroxyvitamin‐D3 modulates JAK–STAT pathway in IL‐12/IFNγ axis leading to Th1 response in experimental allergic encephalomyelitis , 2006 .

[43]  Y. Ohno,et al.  Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons , 2006, Journal of neuroscience research.

[44]  W. Cass,et al.  Calcitriol Protection against Dopamine Loss Induced by Intracerebroventricular Administration of 6-Hydroxydopamine , 2006, Neurochemical Research.

[45]  M. Zasloff.  Fighting infections with vitamin D , 2006, Nature Medicine.

[46]  J. Adams,et al.  Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.

[47]  M. Holick.  High prevalence of vitamin D inadequacy and implications for health. , 2006, Mayo Clinic proceedings.

[48]  A. Kalueff,et al.  Increased severity of chemically induced seizures in mice with partially deleted Vitamin D receptor gene , 2006, Neuroscience Letters.

[49]  Michael A. Kiraly,et al.  Vitamin D as a Neuroactive Substance: Review , 2006, TheScientificWorldJournal.

[50]  J. Rajasingh,et al.  1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. , 2006, Journal of neuroscience research.

[51]  S. Madronich,et al.  Epidemic influenza and vitamin , 2006 .

[52]  P. Pozzilli,et al.  Low Levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in Patients with Newly Diagnosed Type 1 Diabetes , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[53]  M. Holick.  The vitamin D epidemic and its health consequences. , 2005, The Journal of nutrition.

[54]  John H. White,et al.  Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. , 2005, Molecular endocrinology.

[55]  A. Kalueff,et al.  Anticonvulsant effects of 1,25-dihydroxyvitamin D in chemically induced seizures in mice , 2005, Brain Research Bulletin.

[56]  K. Spach,et al.  Vitamin D3 Confers Protection from Autoimmune Encephalomyelitis Only in Female Mice1 , 2005, The Journal of Immunology.

[57]  M. Lynch,et al.  Evidence that vitamin D3 reverses age-related inflammatory changes in the rat hippocampus. , 2005, Biochemical Society transactions.

[58]  H. Koeffler,et al.  Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up‐regulated in myeloid cells by 1,25‐dihydroxyvitamin D3 , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  Kwang-Soo Lee,et al.  Association of Vitamin D Receptor Gene Polymorphism and Parkinson's Disease in Koreans , 2005, Journal of Korean medical science.

[60]  M. Farach-Carson,et al.  Identification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS)-binding protein in rat IEC-6 cells , 2005, Steroids.

[61]  A. Mackay-Sim,et al.  Developmental Vitamin D3 deficiency alters the adult rat brain , 2005, Brain Research Bulletin.

[62]  J. McGrath,et al.  Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.

[63]  H. Richter,et al.  25-hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid , 1984, Klinische Wochenschrift.

[64]  Steven A. Smith,et al.  Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. , 2005, Journal of chemical neuroanatomy.

[65]  A. Berdal,et al.  Modulation of 1α,25‐dihydroxyvitamin D3‐membrane associated, rapid response steroid binding protein expression in mouse odontoblasts by 1α,25‐(OH)2D3 , 2005 .

[66]  A. Berdal,et al.  Modulation of 1alpha,25-dihydroxyvitamin D3-membrane associated, rapid response steroid binding protein expression in mouse odontoblasts by 1alpha,25-(OH)2D3. , 2005, Journal of cellular biochemistry.

[67]  E. Cantor-Graae,et al.  Schizophrenia and migration: a meta-analysis and review. , 2005, The American journal of psychiatry.

[68]  P. Rothwell,et al.  Timing of birth and risk of multiple sclerosis: population based study , 2004, BMJ : British Medical Journal.

[69]  M. Cantorna,et al.  Mounting Evidence for Vitamin D as an Environmental Factor Affecting Autoimmune Disease Prevalence , 2004, Experimental biology and medicine.

[70]  D. Hale.  Biological effects of induction immunosuppression. , 2004, Current opinion in immunology.

[71]  T. Yamamura,et al.  The regulatory role of natural killer cells in multiple sclerosis. , 2004, Brain : a journal of neurology.

[72]  Tsuyoshi Kayo,et al.  Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. , 2004, Physiological genomics.

[73]  S. Emans,et al.  Prevalence of vitamin D deficiency among healthy adolescents. , 2004, Archives of pediatrics & adolescent medicine.

[74]  M. Farach-Carson,et al.  Identification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS) binding protein , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[75]  Peter B. Jones,et al.  Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study , 2004, Schizophrenia Research.

[76]  M. Hutchinson,et al.  Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[77]  J. Cerhan,et al.  Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. , 2004, Arthritis and rheumatism.

[78]  R. Yolken,et al.  Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera , 2003, Schizophrenia Research.

[79]  T. Dwyer,et al.  Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study , 2003, BMJ : British Medical Journal.

[80]  D. Eyles,et al.  1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons , 2003, Neuroscience Letters.

[81]  A. Mackay-Sim,et al.  Vitamin d3 and brain development , 2003, Neuroscience.

[82]  M. Desjardins,et al.  ER-mediated phagocytosis: a new membrane for new functions , 2003, Nature Reviews Immunology.

[83]  P. Brachet,et al.  Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system , 2003, Acta Neuropathologica.

[84]  A. O’Garra,et al.  In vitro generation of IL-10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by Th1- and Th2-inducing cytokines. , 2003, Immunology letters.

[85]  E. Torrey,et al.  A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. , 2003, Schizophrenia bulletin.

[86]  R. Perez-Fernandez,et al.  1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. , 2002, Brain research. Molecular brain research.

[87]  T. Meehan,et al.  The vitamin D receptor is necessary for 1α,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice ☆ , 2002 .

[88]  B. Dawson-Hughes,et al.  Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. , 2002, Bone.

[89]  C. Mathieu,et al.  The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. , 2002, Trends in molecular medicine.

[90]  François Berger,et al.  New clues about vitamin D functions in the nervous system , 2002, Trends in Endocrinology & Metabolism.

[91]  M. Smyth,et al.  The Role of NK Cells in Autoimmune Disease , 2002, Autoimmunity.

[92]  T. Meehan,et al.  The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. , 2002, Archives of biochemistry and biophysics.

[93]  Jorge R. Oksenberg,et al.  The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease , 2001, Science.

[94]  N. Reiner,et al.  1α,25-Dihydroxyvitamin D3-induced Monocyte Antimycobacterial Activity Is Regulated by Phosphatidylinositol 3-Kinase and Mediated by the NADPH-dependent Phagocyte Oxidase* , 2001, The Journal of Biological Chemistry.

[95]  J. Goverman,et al.  Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D3 prevention of experimental autoimmune encephalomyelitis , 2001, Journal of Neuroimmunology.

[96]  B. Hoffer,et al.  Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats , 2001, Brain Research.

[97]  R. Kumar,et al.  Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[98]  T. Yamamura,et al.  Natural killer type 2 bias in remission of multiple sclerosis. , 2001, The Journal of clinical investigation.

[99]  J. Kurtzke,et al.  Multiple sclerosis in the Faroe Islands: an epitome. , 2001, Journal of clinical epidemiology.

[100]  J. Y. Wang,et al.  Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. , 2001, Brain research.

[101]  E. Falkenstein,et al.  Multiple actions of steroid hormones--a focus on rapid, nongenomic effects. , 2000, Pharmacological reviews.

[102]  S. Kikuchi,et al.  Effect of 1,25‐dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L‐buthionine sulfoximine and 1‐methyl‐4‐phenylpyridine , 2000, Journal of neuroscience research.

[103]  K. Myhr,et al.  Effect of dietary advice and n‐3 supplementation in newly diagnosed MS patients , 2000, Acta neurologica Scandinavica.

[104]  R. Vieth,et al.  Vitamin D and seasonal fluctuations of gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2000, Annals of neurology.

[105]  P. Brachet,et al.  Rat oligodendrocytes express the vitamin D3 receptor and respond to 1,25‐dihydroxyvitamin D3 , 2000, Glia.

[106]  S. Stepkowski,et al.  Molecular targets for existing and novel immunosuppressive drugs , 2000, Expert Reviews in Molecular Medicine.

[107]  R. Yolken,et al.  Seasonal Birth Patterns of Neurological Disorders , 2000, Neuroepidemiology.

[108]  T. Y. Chan,et al.  Vitamin D Deficiency and Susceptibility to Tuberculosis , 2000, Calcified Tissue International.

[109]  G. Martino,et al.  Inhibition of Th1 development and treatment of chronic‐relapsing experimental allergic encephalomyelitis by a non‐hypercalcemic analogue of 1,25‐dihydroxyvitamin D3 , 2000, European journal of immunology.

[110]  C. Gössl,et al.  Seasonal fluctuations of gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2000, Annals of neurology.

[111]  D. English,et al.  Multiple sclerosis in Australia: prognostic factors , 2000, Journal of Clinical Neuroscience.

[112]  F. Nashold,et al.  1,25-Dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[113]  M. Cantorna,et al.  Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[114]  J. Mcgrath.  Hypothesis: Is low prenatal vitamin D a risk-modifying factor for schizophrenia? , 1999, Schizophrenia Research.

[115]  M. Hernán,et al.  Geographic variation of MS incidence in two prospective studies of US women , 1999, Neurology.

[116]  N. Pejnović,et al.  Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. , 1999, Clinical and experimental rheumatology.

[117]  M. Lawson,et al.  Dietary and lifestyle factors affecting plasma vitamin D levels in Asian children living in England , 1999, European Journal of Clinical Nutrition.

[118]  C. Beaufort.  The EURODIAB Substudy 2 Study Group Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus , 1999 .

[119]  V. Kadirkamanathan.  Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus , 1999, Diabetologia.

[120]  Lars Klareskog,et al.  A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen‐induced arthritis (CIA) without causing hypercalcaemia , 1998, Clinical and experimental immunology.

[121]  A. Santoni,et al.  Vitamin D3: a transcriptional modulator of the interferon‐γ gene , 1998 .

[122]  Looker Ac,et al.  Hypovitaminosis D in medical inpatients. , 1998 .

[123]  R. Utiger.  The need for more vitamin D. , 1998, The New England journal of medicine.

[124]  P. Brachet,et al.  Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25‐dihydroxyvitamin D3 , 1998, Glia.

[125]  H. DeLuca,et al.  1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. , 1998, The Journal of nutrition.

[126]  A. Santoni,et al.  Vitamin D3: a transcriptional modulator of the interferon-gamma gene. , 1998, European journal of immunology.

[127]  P. Brachet,et al.  1,25-Dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. , 1998, Journal of neuroscience research.

[128]  E. Gunter,et al.  Hypovitaminosis D in medical inpatients. , 1998, The New England journal of medicine.

[129]  M. Wallin,et al.  Multiple sclerosis in the Faroe Islands , 1997, Acta neurologica Scandinavica.

[130]  D. Miller,et al.  Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis , 1997, The Lancet.

[131]  P. Brachet,et al.  1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. , 1997, Brain research. Molecular brain research.

[132]  M. Garabédian,et al.  Subclinical vitamin D deficiency in neonates: definition and response to vitamin D supplements. , 1997, The American journal of clinical nutrition.

[133]  P. Galan,et al.  Prevalence of Vitamin D Insufficiency in an Adult Normal Population , 1997, Osteoporosis International.

[134]  P. Brachet,et al.  1,25 Dihydroxyvitamin D3 Exerts Regional Effects in the Central Nervous System during Experimental Allergic Encephalomyelitis , 1996, Journal of neuropathology and experimental neurology.

[135]  H. DeLuca,et al.  1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[136]  B. Weinshenker,et al.  Epidemiology of multiple sclerosis. , 1996, Neurologic clinics.

[137]  M. Berk,et al.  Season of Birth and Schizophrenia: Southern Hemisphere Data , 1996, The Australian and New Zealand journal of psychiatry.

[138]  E. Stachowiak,et al.  Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. , 1996, Brain research. Molecular brain research.

[139]  L. Freedman,et al.  Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor , 1995, Molecular and cellular biology.

[140]  S. Sasaki,et al.  Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. , 1995, American journal of epidemiology.

[141]  L. Gerstenfeld,et al.  Inhibitory effects of 1,25(OH)2 vitamin D3 on collagen type I, osteopontin, and osteocalcin gene expression in chicken osteoblasts , 1995, Journal of cellular biochemistry.

[142]  H. Mcdevitt,et al.  Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. , 1995, Immunology today.

[143]  P. Brachet,et al.  1,25‐Dihydroxyvitamin D3 regulates NT‐3, NT‐4 but not BDNF mRNA in astrocytes , 1994, Neuroreport.

[144]  P. Brachet,et al.  1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. , 1994, Brain research. Molecular brain research.

[145]  J. Mcleod,et al.  Epidemiology of multiple sclerosis in Australia: With NSW and SA survey results , 1994, The Medical journal of Australia.

[146]  S. Carswell,et al.  Chronic 1,25-dihydroxyvitamin D3-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain , 1994, Brain Research.

[147]  D. Miller,et al.  The British Isles survey of multiple sclerosis in twins , 1994, Neurology.

[148]  P. Brachet,et al.  Expression of 25(OH) vitamin D3 24-hydroxylase gene in glial cells. , 1993, Neuroreport.

[149]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[150]  C. Poser.  Prevalence of multiple sclerosis , 1992, Annals of neurology.

[151]  P. Mortensen,et al.  Season of birth in multiple sclerosis , 1992, Acta neurologica Scandinavica.

[152]  J M Lemire,et al.  1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. , 1991, The Journal of clinical investigation.

[153]  R. Houlgatte,et al.  1,25‐Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis , 1991, Journal of neuroscience research.

[154]  F. Reinholt,et al.  Osteopontin--a possible anchor of osteoclasts to bone. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[155]  J. Abe,et al.  Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin D3. , 1990, Journal of nutritional science and vitaminology.

[156]  S. Jordan,et al.  1,25 dihydroxyvitamin-D3 regulation of immunoglobulin production in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. , 1989, Journal of autoimmunity.

[157]  K. Haglid,et al.  Parvalbumin increases in the caudate putamen of rats with vitamin D hypervitaminosis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[158]  J. Fawcett,et al.  Geographic distribution of MS in New Zealand , 1988, Neurology.

[159]  A. J. Crowle,et al.  Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages , 1987, Infection and immunity.

[160]  G. Rodan,et al.  Tissue specificity and developmental expression of rat osteopontin. , 1987, Biochemical and biophysical research communications.

[161]  J. Kaprio,et al.  Multiple sclerosis in a nationwide series of twins , 1987, Neurology.

[162]  D. Paty,et al.  A population-based study of multiple sclerosis in twins. , 1986, The New England journal of medicine.

[163]  P. Goldberg,et al.  Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. , 1986, Medical hypotheses.

[164]  G. Rook,et al.  Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. , 1986, Immunology.

[165]  B. Källén,et al.  A study of some immunological variables in twins, discordant for multiple sclerosis. , 1985, European neurology.

[166]  M. Fanger,et al.  Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). , 1984, The Journal of clinical investigation.

[167]  J. Adams,et al.  1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. , 1984, The Journal of clinical investigation.

[168]  A. Siegel,et al.  Administration of 1,25-dihydroxyvitamin D3 results in the elevation of hippocampal seizure threshold levels in rats , 1984, Brain Research.

[169]  McDonald Jl.  Nutritional fact and fiction. , 1984 .

[170]  J. McDonald.  Nutritional fact and fiction. , 1984, Alumni bulletin - School of Dentistry, Indiana University.

[171]  T. Markestad,et al.  Vitamin D metabolism in normal and hypoparathyroid pregnancy and lactation , 1983, British journal of obstetrics and gynaecology.

[172]  G. Beebe,et al.  Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis. , 1983, Journal of chronic diseases.

[173]  A. Sadovnick,et al.  Prevalence of multiple sclerosis. , 1982, Canadian Medical Association journal.

[174]  H. DeLuca,et al.  Brain target sites for 1,25-dihydroxyvitamin D3. , 1982, Science.

[175]  D. McFarlin,et al.  Multiple sclerosis in twins , 1980, Neurology.

[176]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[177]  J. Haddad,et al.  Perinatal vitamin D metabolism. III. Factors influencing late gestational human serum 25-hydroxyvitamin D. , 1976, American journal of obstetrics and gynecology.

[178]  J. Haddad,et al.  Perinatal vitamin D metabolism , 1975 .

[179]  B. Agranoff,et al.  Diet and the geographical distribution of multiple sclerosis. , 1974, Lancet.

[180]  P. Goldberg.  Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. (A viewpoint). Part 1. Sunlight, dietary factors and epidemiology. , 1974 .

[181]  G. Gottlieb,et al.  DEVELOPMENT REFLEXES: THE REAPPEARANCE OF FŒTAL AND NEONATAL REFLEXES IN AGED PATIENTS , 1968 .

[182]  M. Alter,et al.  Geographical considerations in multiple sclerosis. , 1967, Brain : a journal of neurology.

[183]  R. P. Mackay,et al.  Multiple Sclerosis in Twins and Their Relatives: Final Report , 1966 .

[184]  R. P. Mackay,et al.  Multiple sclerosis in twins and their relatives. , 1966, Archives of Neurology.

[185]  M. Eadie,et al.  The prevalence of multiple sclerosis in Australia. , 1962, Brain : a journal of neurology.

[186]  E. Acheson,et al.  SOME COMMENTS ON THE RELATIONSHIP OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS TO LATITUDE, SOLAR RADIATION, AND OTHER VARIABLES , 1960, Acta psychiatrica Scandinavica. Supplementum.

[187]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[188]  A. Hess.  ON THE INDUCTION OF ANTIRACHITIC PROPERTIES IN RATIONS BY EXPOSURE TO LIGHT. , 1924, Science.

[189]  H. Steenbock.  THE INDUCTION OF GROWTH PROMOTING AND CALCIFYING PROPERTIES IN A RATION BY EXPOSURE TO LIGHT. , 1924, Science.

[190]  E. Hume,et al.  The Effect of Irradiation of the Environment with Ultra-violet Light upon the Growth and Calcification of Rats, fed on a Diet Deficient in Fat-soluble Vitamins. The Part Played by Irradiated Sawdust. , 1924, The Biochemical journal.